Duality Advisers’s Charles River Laboratories CRL Stock Holding History

Duality Advisers’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,622	Closed	-$1.23M	–	595
2022 Q4	$1.23M	Buy	+5,622	New	+$1.23M	0.14%	267
2022 Q3	–	Sell	-13,609	Closed	-$2.91M	–	571
2022 Q2	$2.91M	Buy	13,609 +7,690	+130%	+$1.88M	0.29%	116
2022 Q1	$1.68M	Buy	5,919 +403	+7%	+$124K	0.18%	194
2021 Q4	$2.08M	Buy	+5,516	New	+$2.14M	0.23%	172

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Duality Advisers's CRL Position: Q1 2023 in Review

Duality Advisers sold out of Charles River Laboratories (CRL) in Q1 2023, closing a stake of 5,622 shares — an estimated $1.23M sold.

Duality Advisers first reported a position in CRL in Q4 2021 and held it in 4 quarters. The position peaked at $2.91M in Q2 2022. 620 funds tracked by Wall St. Rank hold CRL as of Q1 2023.

Duality Advisers reported no remaining Charles River Laboratories position as of Q1 2023 after selling out during the quarter.
Duality Advisers sold 5,622 Charles River Laboratories shares in Q1 2023, an estimated $1.23M.
Duality Advisers first reported a position in Charles River Laboratories in Q4 2021 and held it in 4 quarters.
Duality Advisers's Charles River Laboratories position peaked at $2.91M in Q2 2022.
620 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2023.

Based on Duality Advisers's 13F filing for Q1 2023, filed 27 Jun 2023.